AEON Biopharma

AEON

Market cap $12.9M

AEON Hedge Fund Activity: Q1 2026 in Review

24 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2026, worth a combined $2.8M — up 68% from $1.67M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new AEON positions and 5 closed out — a net gain of 4 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Dauntless Investment Group, adding an estimated $443K. The largest seller was XTX Topco, cutting an estimated $40.7K.

• 24 institutional investors held AEON Biopharma (AEON) as of Q1 2026, up from 22 in Q4 2025.
• Funds reported $2.8M of AEON Biopharma stock for Q1 2026, up 68% quarter-over-quarter.
• 9 funds opened new AEON Biopharma positions in Q1 2026 and 5 closed out, a net change of +4 holders.
• The largest AEON Biopharma buyer in Q1 2026 was Dauntless Investment Group, an estimated $443K added.
• The largest AEON Biopharma seller in Q1 2026 was XTX Topco, an estimated $40.7K sold.

Based on aggregated 13F filings for Q1 2026.